Announcements Trials
Browse Landscape

Phase

Phase 2 20Phase 3 10Phase 2/3 5Phase NA 4Phase 1/2 4Phase 4 2Phase 1 1

Status

Completed 31Terminated 11Withdrawn 4Active not recruiting 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Childhood Solid Tumor, Protocol Specific 1

Interventions

Cyclophosphamide 49fludarabine 37Injections 32Gemcitabine 24Paclitaxel 23Cisplatin 21pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 13Nivolumab 12Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Cetuximab 11Bevacizumab 10Irinotecan 9Immunotherapy, Adoptive 9Drug Therapy 9Etoposide 8sintilimab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7Leucovorin 7Ipilimumab 7Indium 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Busulfan × Clear all
NCT00436761 2013-12-18

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

National Cancer Institute (NCI)

Phase 1 Unknown
20 enrolled
Other solid neoplasm

Unspecified Childhood Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡